Ph.D. Alan J. Main - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
EVP, Innov & Chem Sciences
Signature
/s/ Alan J. Main, Ph.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2023
Net transactions value
-$45,453
Form type
4
Filing time
01 Mar 2023, 15:53:02 UTC
Previous filing
13 Feb 2023
Next filing
12 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +23,300 +13% 198,889 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +8,976 +4.5% 207,865 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +25,667 +12% 233,532 28 Feb 2023 Direct F1
transaction LXRX Common Stock Tax liability $45,453 -20,946 -9% $2.17 212,586 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -23,300 -100% 0 28 Feb 2023 Common Stock 23,300 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -8,976 -50% 8,977 28 Feb 2023 Common Stock 8,976 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -25,667 -33% 51,333 28 Feb 2023 Common Stock 25,667 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.